Meeting
2019 ASCO Annual Meeting
A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).
Authors
Richard D. Kim
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
Richard D. Kim , Dae Won Kim , Olatunji B. Alese , Daneng Li , Neal Shah , Michael J. Schell , Jun Min Zhou , Vincent Chung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT02829918
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4097)
DOI
10.1200/JCO.2019.37.15_suppl.4097
Abstract #
4097
Poster Bd #
202
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
QUIC: Phase 2 study of gemcitabine, cisplatin, quemliclustat (AB680), and zimberelimab (AB122) during first-line treatment of advanced biliary tract cancers (BTC)—Big Ten Cancer Research Consortium study BTCRC-GI22-564.
First Author: John Ebben
Poster
2019 ASCO Annual Meeting
A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.
First Author: Vaibhav Sahai
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2024 ASCO Gastrointestinal Cancers Symposium
ZSAB-TOP: A phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC).
First Author: Jia Fan